semaglutide
Regeneration vs degeneration — where this fits
The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.
Why it would work (logic chain)
No mechanism chain catalogued yet.
How many people take it
There is no reliable global count of how many people take this compound. That number is not in this ledger.
What we can count from this ledger:
- 0 anecdote source(s) (posts, threads, comments)
- 0 anecdote-tier claim(s) derived from them
Logic: Without catalogued Reddit/X posts, this article cannot answer how many people take it — only what studies exist.
Evidence inventory
This is a count of what is in this ledger — not a claim about all research worldwide.
- Scientific sources catalogued (PubMed, trials, reviews): 9
- Claims tagged human evidence: 0
- Claims tagged preclinical (animal/lab): 0
- Claims tagged anecdotal: 0
- Reddit posts catalogued: 0
- X posts catalogued: 0
- Other anecdote sources (YouTube, Instagram, etc.): 0
- Total sources in chain: 9
Logic: Studies exist in the ledger, but none are graded as strong human proof for the uses people discuss online. Animal and lab work is not the same as proof in people.
Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.
Quantified confidence (this ledger): 0.23 / 1.00 — low — animal and anecdote heavy
Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.
What scientists say
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (source s1)
71-week RCT: -13.6% weight loss with 25 mg oral sema vs -2.2% placebo; more GI AEs.
Evidence type: Published research.
Once-weekly semaglutide 7·2 mg in adults with obesity (source s2)
Phase 3 trial of higher-dose semaglutide 7.2 mg for obesity.
Evidence type: Published research.
Semaglutide in Adults with Type 1 Diabetes and Obesity (source s3)
RCT evaluating semaglutide in T1D + obesity.
Evidence type: Published research.
The expanding role of semaglutide: beyond glycemic control (source s4)
2025 review on semaglutide's expanding indications (NAFLD, HF, PCOS, etc.).
Evidence type: Published research.
Phase III Clinical Study on the Efficacy and Safety of Semaglutide (source s5)
New Phase III trial registration for semaglutide (Jul 2025).
Evidence type: Published research.
Semaglutide in cardiovascular and kidney disease (source s6)
Discusses semaglutide benefits in CV and kidney outcomes.
Evidence type: Published research.
Weight Loss in Adults Using Semaglutide (Real-world Study) (source s7)
Real-world study on semaglutide weight loss, published Jun 2026.
Evidence type: Published research.
Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in ... (source s8)
Study on weight loss efficacy of semaglutide 2.4 mg.
Evidence type: Published research.
Semaglutide and Hospitalizations in Patients With Obesity ... (source s9)
Exploratory analysis from SELECT trial on hospitalizations.
Evidence type: Published research.
---
Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.
Ask this article · 2 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.